ValuEngine downgraded shares of Compugen (NASDAQ:CGEN) from a hold rating to a sell rating in a research report released on Wednesday.
Separately, Zacks Investment Research lowered Compugen from a hold rating to a sell rating in a research report on Monday, February 26th.
Compugen (NASDAQ:CGEN) opened at $4.10 on Wednesday. Compugen has a 52-week low of $2.25 and a 52-week high of $5.40.
Several hedge funds and other institutional investors have recently made changes to their positions in CGEN. Paloma Partners Management Co purchased a new stake in shares of Compugen during the fourth quarter worth about $105,000. Virtu Financial LLC purchased a new stake in shares of Compugen during the fourth quarter worth about $162,000. Jane Street Group LLC purchased a new stake in shares of Compugen during the fourth quarter worth about $192,000. Benjamin F. Edwards & Company Inc. increased its position in shares of Compugen by 35.4% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 85,300 shares of the biotechnology company’s stock worth $213,000 after acquiring an additional 22,305 shares during the last quarter. Finally, Anson Funds Management LP purchased a new stake in shares of Compugen during the fourth quarter worth about $281,000. 23.49% of the stock is currently owned by institutional investors and hedge funds.
Compugen Company Profile
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.